# Patrick M. Moriarty

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/patrick-m-moriarty/

## Facts

| Field | Value |
| --- | --- |
| Citations | 12,449 |
| Field | Lipoproteins and Cardiovascular Health |
| h-index | 52 |
| i10-index | 100 |
| Last Known Institution | University of Kansas Medical Center |
| OpenAlex ID | https://openalex.org/A5002852988 |
| ORCID iD | 0000-0001-5548-4493 |
| Works | 201 |

## Researcher papers

- [Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement](https://scholariq.org/papers/lipoprotein-a-in-atherosclerotic-cardiovascular-disease-and-aortic-stenosis-a/)
- [Lipoprotein(a) Reduction in Persons with Cardiovascular Disease](https://scholariq.org/papers/lipoprotein-a-reduction-in-persons-with-cardiovascular-disease/)
- [Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients](https://scholariq.org/papers/bempedoic-acid-and-cardiovascular-outcomes-in-statin-intolerant-patients/)
- [Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients](https://scholariq.org/papers/familial-hypercholesterolemia-screening-diagnosis-and-management-of-pediatric-2/)
- [Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients](https://scholariq.org/papers/familial-hypercholesterolemia-screening-diagnosis-and-management-of-pediatric/)
- [Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel](https://scholariq.org/papers/defining-severe-familial-hypercholesterolaemia-and-the-implications-for-clinical/)
- [Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel](https://scholariq.org/papers/position-paper-statin-intolerance-an-attempt-at-a-unified-definition-position/)
- [Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial](https://scholariq.org/papers/effects-of-alirocumab-on-cardiovascular-and-metabolic-outcomes-after-acute/)
- [Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia](https://scholariq.org/papers/diagnosis-and-treatment-of-heterozygous-familial-hypercholesterolemia/)
- [The Role of Nutraceuticals in Statin Intolerant Patients](https://scholariq.org/papers/the-role-of-nutraceuticals-in-statin-intolerant-patients/)
- [Statins and almonds to lower lipoproteins (the STALL Study)](https://scholariq.org/papers/statins-and-almonds-to-lower-lipoproteins-the-stall-study/)

## Researcher topics

- [Lipoproteins and Cardiovascular Health](https://scholariq.org/topics/lipoproteins-and-cardiovascular-health/)
- [Diabetes, Cardiovascular Risks, and Lipoproteins](https://scholariq.org/topics/diabetes-cardiovascular-risks-and-lipoproteins/)
- [Lipid metabolism and disorders](https://scholariq.org/topics/lipid-metabolism-and-disorders/)
- [Cancer, Lipids, and Metabolism](https://scholariq.org/topics/cancer-lipids-and-metabolism/)
- [Antiplatelet Therapy and Cardiovascular Diseases](https://scholariq.org/topics/antiplatelet-therapy-and-cardiovascular-diseases/)

## Researcher university

- [University of Kansas Medical Center](https://scholariq.org/institutions/university-of-kansas-medical-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.